
A safe and effective gel allowing women to protect themselves from HIV may be available by 2010 if current trials involving thousands of women are successful, researchers said Sunday. Gita Ramjee, director of the HIV prevention research unit at South Africa’s Medical Research Council, said microbe-killing vaginal gels offer huge potential for stemming the epidemic, especially in societies where men are reluctant to use a condom. Ramjee said that five separate clinical trials are under way involving 12,000 people in South Africa and thousands in other countries. Results should be ready in the next two years, she said.
“We have waited 25 years to address the epidemic, so 2008 is really not too much longer to wait,” she told a press conference before an international conference on microbicides. She said that if governments fast-tracked the regulatory approval process, the gels might be on the market by 2010—although she cautioned this is the earliest anticipated date.
The conference, cosponsored by the World Health Organization, brings together more than 1,000 scientists and researchers from around the world.
HIV infection is rising more rapidly among women than men in many parts of the world. Half of all adults living with HIV are female, according to United Nations figures. In sub-Saharan Africa, home to more than 25 million of the nearly 40 million people infected around the world, women account for nearly 60% of infections, with most acquired through heterosexual intercourse. Yet strong taboos still exist on the continent against the use of condoms.
The London School of Hygiene and Tropical Medicine has calculated that a microbicide that is 60% effective against HIV and used by only 20% of women in 73 developing countries over three years could prevent 2.5 million infections.
Microbicides can take the form of a gel, cream, sponge, or ring that releases an ingredient that can kill or deactivate HIV during intercourse.
Although studies to date have focused on preventing HIV infections in females through heterosexual intercourse, many scientists believe microbicides also may offer some protection against HIV for gay men who engage in anal sex, particularly when used in conjunction with condoms.
Coinciding with the start of the conference, South African AIDS activists launched a new campaign to try to prevent 2 million new HIV infections by 2010.
The Treatment Action Campaign, which until now has focused on improving access to medication, said it would press the government to provide more condoms and improve sex education.
“There is a crisis of prevention in this country,” said Zackie Achmat, president of the campaign. “There are 1,400 new infections every day. That must stop.”
Up to 6 million South Africans are infected with HIV, the highest number of any country. It is projected that 2.5 million more may become infected by 2010. (AP, with additional reporting by The Advocate)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
Comments that do not concern specific articles in The Advocate or on Advocate.com will not be posted or published. See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.